Related Experiment Video
Updated: Aug 6, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
[Fibrinolytic therapy in deep venous thrombosis of the upper and lower extremity]
Insights
Fibrinolytic therapy using streptokinase or urokinase effectively treats deep vein thrombosis, with best results for clots up to two weeks old. Extended treatment beyond 96 hours improves outcomes, especially for lower limb deep vein thrombosis.
Area of Science:
- Vascular Medicine
- Thrombosis Management
- Pharmacology
Context:
- Deep venous thrombosis (DVT) affects major veins, including iliac, femoropopliteal, and subclavian segments.
- Fibrinolytic therapy offers a potential treatment for DVT, aiming to restore venous patency.
- Evaluating the efficacy and safety of fibrinolytic agents in a diverse DVT patient cohort is crucial.
Purpose:
- To assess the effectiveness of fibrinolytic therapy in treating various types of deep venous thromboses.
- To determine the optimal duration and timing for administering fibrinolytic agents based on thrombus age.
- To document the safety profile and side effects associated with streptokinase and urokinase treatment.
Summary:
- Fifty-nine patients with 60 DVTs received fibrinolytic therapy with streptokinase (SK), urokinase (UK), or both.
- Recanalization rates varied by thrombus age, with higher success for clots less than two weeks old (up to 57% complete).
- Common side effects included decreased hemoglobin and fever; bleeding required treatment interruption in two cases.
Impact:
- Fibrinolytic therapy is justified for DVTs up to 14 days old, and potentially up to 28 days, considering medical and social benefits.
- Extending therapy beyond 96 hours significantly improves outcomes for lower limb DVTs.
- Complete recanalization achieved with SK or UK leads to good long-term venous drainage capacity, warranting intensive care unit administration.
Abstract:
Fibrinolytic therapy was carried out in 59 patients suffering from a total of 60 deep venous thromboses of the iliac segment (n = 24), the femoropopliteal segment (n = 18), the deep calf veins (n = 2), or the subclavian vein (n = 16). 46 patients received streptokinase (SK), 4 were given urokinase (UK), and 10 were treated with streptokinase followed by urokinase (SK + UK). The duration of fibrinolytic therapy was between 19 and 596 hours (x = 166 +/- 111 hrs). Phlebographic examination was used to determine the location of the thrombotic occlusion as well as to evaluate therapeutic results. To assure sufficient anticoagulatory protection during therapy with streptokinase the dose of streptokinase was either reduced by steps of 20,000 U/hr to a minimum of 40,000 U/hr or heparin was added as a continuous infusion. Urokinase was administered with a mean loading dose of 75,000 IU followed by an average maintenance dose of 40,000 IU/hr; it was always given in combination with heparin. When therapeutic success was graded as complete/partial/no recanalisation, the following results were obtained: thrombotic occlusion up to 1 week old 35%/48%/17%; up to 2 weeks old 57%/14%/29%; 3 or 4 weeks old 12%/38%/50%; older than 4 weeks 13%/37%/50%. The two most common side effects were a fall of the hemoglobin and a rise of body temperature. Treatment with SK had to be interrupted for bleeding in two cases. One patient diet after rupture of the liver and of the spleen following development of subcapsular hematoma in these organs, 3 patients survived pulmonary embolism without major long-term impairment. Considering medical and social aspects (preservation of capability for working in young adults) it appears justified to administer fibrinolytic agents up to a thrombus age of 14 days, in some cases even up to a thrombus age of 28 days. Good results in cases of deep vein thrombosis of the lower limbs are often obtained only when fibrinolytic therapy is extended beyond 96 hours. It should be performed in intensive care units only. Follow-up examinations of the venous drainage capacity up to 2 years after fibrinolytic therapy document the good therapeutic effect that is warrented by streptokinase or urokinase induced complete recanalisation.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

